Patent ID: 6719971
Filing Date: 2004-04-13
Classification: A61K,A61P,C07K,G06F

Abstract:
A method of treating cancer overexpressing p185HER2 in a patient comprising administering to the patient a therapeutically effective amount of a humanized antibody that specifically binds p185HER2, wherein the antibody comprises the VL and VH domains of an antibody selected from the group consisting of huMAb4D5-3 (SEQ ID NOS. 27 and 28, respectively), huMAb4D5-4 (SEQ ID NOS. 29 and 30, respectively), huMAb4D5-5 (SEQ ID NOS. 1 and 2, respectively), huMAb4D5-6 (SEQ ID NOS. 31 and 32, respectively), huMAb4D5-7 (SEQ ID NOS. 33 and 34, respectively), and huMAb4D5-8 (SEQ ID NOS. 35 and 36, respectively).